Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab plus albumin paclitaxel + cisplatin vs albumin paclitaxel + cisplatin as neoadjuvant therapy in esophageal squamous cell carcinoma
ChiCTR2100045992Phase 2Recruiting
- Sponsor
- Harbin Medical University Cancer Hospital
- Start
- Dec 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of sintilimab in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by Harbin Medical University Cancer Hospital. Primary endpoint: Pathological partial remission rate (mPR). Started Dec 2020; status: recruiting.
02
Drugs
sintilimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2100045992.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100045992.